+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Blood Plasma: Market Shares, Strategies, and Forecasts, Worldwide, 2018 to 2024

  • ID: 4666808
  • Report
  • October 2018
  • Region: Global
  • 338 Pages
  • Wintergreen Research, Inc
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now
Sales of Blood Therapeutics were $30.9 Billion in 2017 and by 2024, These Products will Reach $57.5 Billion, Reflecting a Five-Year CAGR of 8.2%.

FEATURED COMPANIES

  • ANZCO Foods
  • BPL Group
  • ExCel Bio
  • LFB Biotechnologies
  • Octopharma AG
  • Sigma-Aldrich
  • MORE

This 2018 study has 338 pages, 148 tables and figures. Worldwide markets are poised to achieve continuing growth as animal and human blood is further fractionated to address more disease treatments and becomes more effective in the research and development aspects of medical care delivery.

Blood is for most species the essence of life. Blood plasma provides significant health benefits. The varieties of proteins and other components of blood are in demand worldwide. Blood proves its value by managing a variety of ways to treat disease.

The plasma proteins or derivatives in blood are extracted via the fractionation process. A range of valuable products are manufactured from blood plasma through fractionation. Fractionation occurs in tanks at near freezing temperatures. Fractionation is used to maintain the integrity of the proteins in plasma. This process includes a phase of introducing various viral inactivation procedures.

Blood plasma offers high value for its volume and weight. One refrigerated container might be worth more than an entire shipload of grain. Blood provides significant health benefits to people. Blood exports boost U.S. exports with minimal carbon emissions.

Liver disease is a major cause of illness and death worldwide. In China, 400 million people have liver diseases, primarily viral hepatitis (predominantly hepatitis B virus [HBV]). Nonalcoholic fatty liver disease and alcoholic liver diseases are also prevalent diagnoses.

The blood plasma market is driven in part by China, and by demand from China for high-quality blood from the US. Chinese patients consumed 400 metric tons of serum albumin in 2017, half of the global total of that blood protein. The necessary supply could be provided by the Chinese population, but, many of them are afraid to donate blood.

The reason is a well-remembered 1990s health scare in which tens of thousands of farmers who had been paid to donate blood acquired HIV from unsanitary needles. The ensuing scandal was covered up by the government.

As a result, China has to import about 60% of its serum albumin-and the ever-rising demand has driven up prices. American companies have an edge in the Chinese markets because of the quality of the blood collected. The edge is apparent in the fact that three foreign companies account for 88% of China’s serum albumin imports.

The billion-dollar market for blood worldwide has a variety of participants. Thermo Fisher Scientific has the largest market participation. Sales of blood therapeutics were $30.9 billion in 2017. By 2024, these products reach $57.5 billion, reflecting a five-year CAGR of 8.2%.

Key Topics:

  • Blood
  • Plasma proteins
  • Immunoglobulins
  • Albumin
  • Hemophilia factor proteins
  • Fractionation
  • Serum
  • Blood Plasma
  • Proteins Components of Blood
  • Liver Disease
  • Viral Hepatitis (Predominantly Hepatitis B)
  • Mandatory HCV Screening
  • Blood Transfusion
  • High Mortality From Liver Diseases
  • Serum Albumin, A Substance Found In Human Blood Plasma
  • Blood Acquired HIV from Unsanitary Needles

Report Methodology:

This is the 807th report in a series of primary market research reports that provide forecasts in communications, telecommunications, the Internet, computer, software, telephone equipment, health equipment, and energy. Automated process and significant growth potential are priorities in topic selection.

The project leaders take direct responsibility for writing and preparing each report. They have significant experience in preparing industry studies. Forecasts are based on primary research and proprietary data bases. The primary research is conducted by talking to customers, distributors and companies. The survey data is not enough to make an accurate assessment of market size, so the researcher looks at the value of shipments and the average price to achieve market assessments. Our track record in achieving accuracy is unsurpassed in the industry. We are known for being able to develop accurate market shares and projections.

The analyst process is concentrated on getting good market numbers. This process involves looking at the markets from several different perspectives, including vendor shipments. The interview process is an essential aspect as well. We do have a lot of granular analysis of the different shipments by vendor in the study and addenda prepared after the study was published if that is appropriate.

Forecasts reflect analysis of the market trends in the segment and related segments. Unit and dollar shipments are analyzed through consideration of dollar volume of each market participant in the segment. Installed base analysis and unit analysis is based on interviews and an information search. Market share analysis includes conversations with key customers of products, industry segment leaders, marketing directors, distributors, leading market participants, opinion leaders, and companies seeking to develop measurable market share.

Over 200 in-depth interviews are conducted for each report with a broad range of key participants and industry leaders in the market segment. The researchers establish accurate market forecasts based on economic and market conditions as a base. Use input/output ratios, flow charts, and other economic methods to quantify data. Use in-house analysts who meet stringent quality standards. Interviewing key industry participants, experts and end-users is a central part of the study. Our research includes access to large proprietary databases. Literature search includes analysis of trade publications, government reports, and corporate literature.

Findings and conclusions of this report are based on information gathered from industry sources, including manufacturers, distributors, partners, opinion leaders, and users. Interview data were combined with information gathered through an extensive review of internet and printed sources such as trade publications, trade associations, company literature, and online databases. The projections contained in this report are checked from top down and bottom up analysis to be sure there is congruence from that perspective. The base year for analysis and projection is 2017. With 2017 and several years prior to that as a baseline, market projections were developed for 2018 through 2024. These projections are based on a combination of a consensus among the opinion leader contacts interviewed combined with an understanding of the key market drivers and their impact from a historical and analytical perspective.

The analytical methodologies used to generate the market estimates are based on penetration analyses, similar market analyses, and delta calculations to supplement independent and dependent variable analysis. All analyses are displaying selected descriptions of products and services.

This research includes reference to an ROI model that is part of a series that provides IT systems financial planners access to information that supports analysis of all the numbers that impact management of a product launch or large and complex data center. The methodology used in the models relates to having a sophisticated analytical technique for understanding the impact of workload on processor consumption and cost.

The Publisher has looked at the metrics and independent research to develop assumptions that reflect the actual anticipated usage and cost of systems. Comparative analyses reflect the input of these values into models.

The variables and assumptions provided in the market research study and the ROI models are based on extensive experience in providing research to large enterprise organizations and data centers. The ROI models have lists of servers from different manufacturers, Systems z models from IBM, and labor costs by category around the world.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ANZCO Foods
  • BPL Group
  • ExCel Bio
  • LFB Biotechnologies
  • Octopharma AG
  • Sigma-Aldrich
  • MORE

1. Blood: Market Description And Market Dynamics
1.1 Blood Plasma
1.1.1 Immunotherapy Plus Chemotherapy
1.2 Liver Disease Is A Major Cause Of Illness And Death In China
1.2.1 Fractionation Technique for Manufacture Blood Products from Plasma: Treatment for Chronic Hepatitis B Infection
1.3 Plasma Products Market Trends

2. Blood Market Shares And Forecasts
2.1 Blood Market Driving Forces
2.2 Serum (Blood) Market Shares
2.2.1 Blood Serum Providers To China, Market Shares,
2.2.2 Blood Company Descriptions
2.2.3 Blood Company Descriptions
2.2.4 Intense Competition Comes From Local And Overseas Pharmaceutical Enterprises in China
2.2.5 30 Approved Manufacturers Of Plasma Products in China
2.2.6 Major Competitors in China
2.3 Serum (Blood) Market Forecasts
2.3.1 Blood Market Segments
2.3.2 Transpacific Trade In Human Blood Plasma Products
2.3.3 Tons of Blood Plasma
2.4 Serum (Blood) Market Segment Forecasts
2.4.1 Blood Plasma Protein Treatment Market Segments, Albumin, Polyvalient IVIG/SCIG, Factor X, Factor VIII, Huperimunes
2.4.2 IgG
2.4.3 Blood Immunoglobulin Segment
2.4.4 Blood Market Segment Forecasts, Immunology, Pulmonology, Oncology, Rheumatology, Neurology, Hematology, Transplants and Other Applications
2.4.5 Blood Market Segment Forecasts, Disease Treatment, Cell Culture, Medical Device and Scientific Research
2.4.6 Blood Market Segment Forecasts, Immunology, Pulmonology, Oncology, Rheumatology, Neurology, Hematology, Transplants and Other Applications
2.4.7 Blood Market Is Segmented By Application
2.5 Animal and Bovine Serum Market Segments, FBS, ABS, NBCS, BS, Porcine Sera, Dollars, Worldwide, 2017
2.5.1 Plasma Proteins Market
2.5.2 Plasma Proteins Chinese Market
2.5.3 Blood Basic Proteins Market Prospects
2.5.4 Global Plasma Supply For Fractionation And The Role of the United States
2.5.5 Hep B Treatments
2.5.6 Applications For Processed Bovine Serum
2.5.7 FBS
2.5.8 FBS Cell Culture Process Of Growing Cells Under Controlled Conditions In Vitro
2.5.9 ABS
2.5.10 Newborn Calf Serum NBCS
2.5.11 BCS
2.5.12 Porcine Sera
2.5.13 Biotechnology Industry
2.5.14 Global Animal Health Market
2.6 Serum (Blood) Prices
2.6.1 Corning Bolvine Serum
2.6.2 Millipore / Sigma Aldrich Fetal Bovine Serum, FBS, FCS, Sera,
2.6.3 Prices of Pharmaceutical Plasma Products
2.7 Serum (Blood) Regional Market
2.7.1 US
2.7.2 China
2.7.3 Chinese Clinical Approval For Human Blood Coagulation Factor VIII
2.7.4 Blood Plasma and Serum Providers Improved Fractionation Technologies for China Market, 2017
2.7.5 Blood Plasma and Serum Providers Increasing Market Concentration of Top Players China Market, 2017
2.7.6 China Mutual Aid Blood Donation
2.7.7 China Cord Blood Market For Cord Blood Banking
2.7.8 Reimbursement in China
2.7.9 Asia-Pacific
2.7.10 Europe
2.7.11 Australia
2.7.12 Company Geographical Revenue

3. Serum (Blood) Product Description
3.1 Plasma Source of Life
3.1.1 Plasma Major Component Of Blood
3.1.2 Plasma Carrier For Nutrients, Hormones, Proteins
3.2 Plasma Vital To The Regulation Of Body Functions
3.2.1 Standardization and Application Of Polymerase Chain Reaction (PCR)
3.3 Immunoglobulin Products
3.3.1 Subcutaneous immunoglobulin
3.3.2 Normal human immunoglobulin
3.3.3 Hyperimmune Immunoglobulin Products
3.3.4 Hepatitis B Immunoglobulin
3.3.5 Treatment for Chronic Hepatitis B Infection
3.3.6 Rh(D) immunoglobulin
3.3.7 Tetanus Immunoglobulin
3.3.8 Zoster Immunoglobulin
3.4 Albumin products
3.5 Clotting Factor and Other Products
3.5.1 Factor VIII
3.5.2 Factor IX
3.5.3 Factor VIIa
3.5.4 FEIBA
3.5.5 Prothrombin complex
3.5.6 Antithrombin III
3.5.7 Protein C
3.5.8 Fibrogammin
3.5.9 Factor XI and Factor XIII
3.5.10 C1 Esterase Inhibitor

4. Blood Research And Technology
4.1 Bovine Serum
4.2 Genetically Engineered Blood Products
4.3 Government Regulation
4.3.1 United States Government Regulation
4.3.2 European Government Regulation
4.3.3 Each European Union Member State Has Its Own Procedures for Authorization Of Medicines, Within Its Own Territory,
4.4 Cord Blood
4.5 Chinese Serum Contaminated with AIDS Virus
4.6 Chinese Biological Product Regulations
4.7 Chinese Drug Industry Under Attack

5 Serum (Blood) Company Profiles
5.1 ANZCO Foods / Bovogen Biologicals
5.1.1 Clients and Suppliers
5.1.2 Development and Prospects
5.1.3 ANZCO Foods Jointly Owned by Itoham Foods (Mitsubishi Corporation shareholder), Nippon Suisan Kaisha
5.1.4 ANZCO Foods Animal Serum Product Sub-Lots
5.1.5 ANZCO Foods / Bovogen Biologicals
5.1.6 Bovogen Biologicals
5.1.7 ANZCO Foods Revenue
5.2 Ausgenex Pty Ltd
5.2.1 AusGeneX Revenue
5.3 Avantor
5.3.1 Avantor / VWR Sole Supplier For Cell And Gene Therapy to Catapult.
5.3.2 Avantor / VWR
5.3.3 VWR Animal and Human Blood for Use in DNA/RNA Isolation or for Testing Infectious Diseases
5.3.4 VWR
5.3.5 Avantor Revenue
5.3.6 VWR Revenue
5.3.7 VMR Plasma-Based Biopharmaceutical Manufacturing Industry in China
5.3.8 VWR Suppliers
5.4 Biochrom GmbH
5.5 Biotest AG
5.6 BPL Group
5.7 Cellsera Rutherford
5.7.1 Cellsera Rutherford Certificates and Accreditations
5.7.2 Cellsera Privately owned, 100% Australian company
5.7.3 Cellsera Manufacturing Facility
5.8 Changchun SRbiological
5.8.1 Zen Bio Human Serum & Animal-Free Growth Supplement
5.8.2 Zen Bio Human Serum Technical Advantage Over Animal Serum
5.8.3 Zen-Bio Animal Serum - Cell Culture
5.9 China Biologic Products
5.9.1 China Biologic Sales
5.9.2 China Biologic Acquisition TianXinFu
5.9.3 China Biologic Products Holdings, Revenue
5.9.4 China Biologic Sales Volume Of Products by Segment
5.9.5 China Biologic Research And Development Expenses
5.9.6 China Biologic Products Holdings, Manufacturing Facilities
5.9.7 China Biologic Products Holdings
5.10 Chinese Plasma Market and Acquisitions
5.10.1 Chinese Blood Product Industry
5.10.2 In August 2011, China Shut Down 16 Plasma Stations in Guizhou
5.11 Corning Life Sciences
5.11.1 Corning Life Sciences Operation
5.11.2 Corning Life Sciences Revenue Structure
5.11.3 R&D and Investment
5.11.4 Corning Life Sciences Sera Products
5.11.5 Corning Cell Growth and Differentiation
5.11.6 Corning Cancer Research
5.11.7 Corning Cell Culture
5.11.8 Custom Media and Sterile Solutions
5.11.9 Corning® Fetal Bovine Serum
5.11.10 Corning Regional Presence
5.12 Global Cord Blood Corp.
5.13 CSL
5.13.1 CSL 35 Per Cent Annual Growth in Chinese Albumin Sales
5.13.2 CSL Bought 80 Per Cent Stake In Chinese Plasma Fractionator Wuhan Zhongyuan Ruide Biologics
5.13.3 CSL addresses Market for 100 Million Chinese with Liver Problems
5.14 ExCel Bio
5.15 GE Healthcare Life Sciences
5.15.1 GE HyClone™ Fetal Bovine Serum, Standard
5.15.2 GE Healthcare HyClone™ AdvanceSTEM™ ES Qualified Amino Acids
5.15.3 GE Healthcare HyClone™ Fetal Bovine Serum (Canada), Characterized
5.15.4 GE Healthcare HyClone™ Fetal Bovine Serum, Super Low IgG
5.15.5 GE Healthcare HyClone™ Fetal Bovine Serum, Human Mesenchymal Stem Cell Screened
5.15.6 GE Healthcare HyClone™ Fetal Bovine Serum (New Zealand), Characterized
5.15.7 GE Healthcare HyClone™ Fetal Bovine Serum, Defined
5.15.8 GE Healthcare HyClone™ Fetal Bovine Serum, Characterized
5.15.9 GE Healthcare HyClone™ Fetal Bovine Serum, Tetracycline Screened
5.15.10 GE HyClone™ Bovine Growth Serum
5.15.11 CBMG and GE Healthcare Life Sciences China Partner on CAR T-Cell and Stem Cell Manufacturing
5.16 Grifols S.A. (GRFS)
5.16.1 Grifols U.S. Presence
5.16.2 Grifols Revenue
5.16.3 Grifols Acquires 24 Plasma Donation Centers in the United States
5.16.4 Grifols Plasma Collection
5.16.5 Grifols Bioscience Products and Services
5.17 Hualan Biological Engineering Inc.
5.18 Kedrion S.p.A.
5.18.1 Kedrion Revenue
5.19 Lake Immunogenics
5.19.1 Lake Immunogenics Profile
5.19.2 Lake Immunogenics Operation
5.20 Lanzhou Minhai
5.21 LFB Biotechnologies
5.22 Mallinckrodt
5.23 Merck KGaA / Millipore / Sigma-Aldrich
5.23.1 Sigma-Aldrich Cell Cytotoxicity Assay
5.23.2 USA Origin, Sterile-Filtered, Suitable For Cell Culture, Suitable For Hybridoma
5.23.3 Merck / BioControl Systems
5.24 Moregate Biotech
5.25 Newman Biotech
5.26 Octopharma AG
5.26.1 Octapharma R&D and Investment
5.27 Sanpower Group
5.28 Selborne Biological Services
5.28.1 Selborne Biological Services Animal Blood-Derived Products
5.28.2 Selborne Biological Services Plasma
5.29 Proliant
5.29.1 Proliant Can Produce As Much BSA As The World Uses Each Year
5.29.2 Proliant Closed-Loop Processing
5.29.3 Lauridsen Group / Proliant
5.30 Shanghai RAAS
5.30.1 Shanghai RAAS R&D
5.30.2 Shanghai RAAS Revenue
5.31 Rocky Mountain Biologicals (RMBIO)
5.31.1 Rocky Mountain Biologicals Revenue
5.32 Sanquin
5.33 Takeda / Shire
5.33.1 Shire Pharmaceuticals (SHPG) / Baxalta
5.33.2 Shire Revenue
5.33.3 Shire Hematology
5.33.4 Shire Immunology
5.33.5 Shire Neuroscience
5.33.6 Shire Lysosomal Storage Diseases
5.33.7 Shire Gastrointestinal / Endocrine
5.33.8 Shire HAE
5.33.9 Shire Ophthalmics
5.33.10 Shire / Servier Oncology
5.33.11 Takeda / Shire Financial Goals
5.34 South Pacific Sera
5.35 Thermo Fisher Scientific
5.35.1 Thermo Fisher Scientific Microbiology
5.35.2 Thermo Fisher Scientific Serum Preparation
5.35.3 Thermo Fisher Scientific Plasma Preparation
5.35.4 Thermo Fisher Animal Serum
5.35.5 Thermo Fisher Scientific Quality, Performance, And Consistency Essential To Cell Culture
5.36 Beijing Tiantan Biological Products
5.36.1 Tiantan Bio Sales Model
5.36.2 Tiantan Bio Management Model
5.36.3 Tiantan Bio Profile
5.36.4 Tiantan Bio Operation
5.36.5 Tiantan Bio Revenue Structure
5.36.6 Tiantan Bio R&D and Investment
5.36.7 Tiantan Bio Development and Prospects
5.36.8 Tiantan Biological Products
5.36.9 Beijing Tiantan Biological Products Profile
5.36.10 Beijing Tiantan Biological Products
5.36.11 Tiantan Bio Cosmetic Serum Market
5.37 Wuhan Sanli
5.38 Wolongsong
5.39 ZenBio
5.39.1 ZenBio Human Serum
5.40 Selected Chinese Blood Companies
5.40.1 Global Animal Blood Plasma Products and Derivatives Market
5.40.2 Global Bovine Blood Plasma Derivatives Market
5.40.3 Blood Serum Industry Key Players.
5.40.4 Cosmetic Serum Market
5.40.5 Plasma Fractionation Market

6. The Publisher
6.1 Methodology
6.2 Research Process
6.3 Market Research Study
6.4 Global Market Intelligence Company

List of Figures
Figure 1. Blood Plasma Market Shares Dollars, Worldwide, 2017
Figure 2. Number of Patients with Liver Disease in China and Worldwide
Figure 3. US Diagnosis Of Chronic Hepatitis B (CHB).
Figure 4. Plasma Proteins Industry Market Growth Factors
Figure 5. Blood Market Driving Forces
Figure 6. Blood Plasma Market Shares Dollars, Worldwide, 2017
Figure 7. Blood Plasma Market Shares, Dollars, Worldwide, 2017
Figure 8. Blood Plasma Market Shares Units, Worldwide, 2017
Figure 9. Blood Serum Providers To China, Market Shares, Dollars, Worldwide, 2017
Figure 10. Blood Plasma Company Descriptions
Figure 11. Blood Serum Providers To China, Company Descriptions, Worldwide, 2017
Figure 12. Major Plasma Competitors in China
Figure 13. Blood Plasma and Serum Providers To China Description, 2017
Figure 14. Blood / Plasma / Serum Market Forecasts, Dollars, Worldwide, 2018-2024
Figure 15. Blood Market Forecasts, Dollars, Worldwide, 2018-2024
Figure 16. Blood Plasma Collection Production, Selected Companies, Tons, Worldwide, 2017
Figure 17. Blood Plasma Collection Production, Regional Analysis, Tons, Worldwide, 2017
Figure 18. Blood Plasma Market Categories
Figure 19. Blood Plasma Proteins Market Segments, Albumin, Polyvalient IVIG/SCIG, Factor X, Factor VIII, Huperimunes, Dollars and Percent, Worldwide, 2017
Figure 20. Blood Plasma Proteins Market Segments, Albumin, Polyvalient IVIG/SCIG, Factor X, Factor VIII, Huperimunes, Dollars and Percent, Worldwide, 2012
Figure 21. Blood Plasma Proteins Market Forecasts, Dollars, Worldwide, 2018-2024
Figure 22. Blood Plasma Protein Treatment Market Segments, Albumin, Polyvalient IVIG/SCIG, Factor X, Factor VIII, Huperimunes, Dollars, Worldwide, 2018-2024
Figure 23. Blood Plasma Protein Treatment Market Segments, Albumin, Polyvalient IVIG/SCIG, Factor X, Factor VIII, Huperimunes, Percent, Worldwide, 2018-2024
Figure 24. Immunoglobin Blood Market Segment Forecasts, Dollars and Percent Worldwide, 2018-2024
Figure 25. Blood Market Segment Forecasts, Immunology, Pulmonology, Oncology, Rheumatology, Neurology, Hematology, Transplants and Other Applications, Forecasts, Dollars, Worldwide, 2018-2024
Figure 26. Blood Market Segment Forecasts, Immunology, Pulmonology, Oncology, Rheumatology, Neurology, Hematology, Transplants and Other Applications, Forecasts, Percent, Worldwide, 2018-2024
Figure 27. Blood Market Segment Forecasts, Disease Treatment, Cell Culture, Medical Device and Scientific Research, Dollars, Worldwide, 2018-2024
Figure 28. Blood Market Segment Forecasts, Cell Culture, Medical Device and Scientific Research. Percent, Worldwide, 2018-2024
Figure 29. Blood Market Segment Forecasts, Immunology, Pulmonology, Oncology, Rheumatology, Neurology, Hematology, Transplants and Other Applications, Forecasts, Dollars, Worldwide, 2018-2024
Figure 30. Blood Market Segment Forecasts, Immunology, Pulmonology, Oncology, Rheumatology, Neurology, Hematology, Transplants and Other Applications, Forecasts, Percent, Worldwide, 2018-2024
Figure 31. Blood Plasma Products In The Food Industry
Figure 32. Animal and Bovine Serum Market Segments, FBS, ABS, NBCS, BS, Porcine Sera, Dollars, Worldwide, 2017
Figure 33. Blood Market Forces
Figure 34. Blood Plasma and Serum Providers To China, Market Shares, Dollars, Worldwide, 2017
Figure 35. Blood Plasma and Serum Providers To China Description, 2017
Figure 36. Blood Plasma Proteins Market Segments, Albumin, Polyvalient IVIG/SCIG, Factor X, Factor VIII, Huperimunes, Dollars and Percent, Worldwide, 2017
Figure 37. Blood Plasma Proteins Market Segments, Albumin, Polyvalient IVIG/SCIG, Factor X, Factor VIII, Huperimunes, Dollars and Percent, Worldwide, 2012
Figure 38. Basic Proteins Market Prospects
Figure 39. Regulatory Requirements To Establish A Plasma Collection Station In China
Figure 40. Safety Features at China’s Plasma Collection Stations:
Figure 41. VWR Blood Pricing
Figure 42. Corning Life Sciences
Figure 43. Millipore / Sigma Aldrich Fetal Bovine Serum, FBS, FCS, Sera,
Figure 44. Blood Regional Market Segments, 2017
Figure 45. Blood Regional Market Segments, 2017
Figure 46. Plasma Collection and Release Volumes in China, 2016
Figure 47. Blood Plasma and Serum Providers High Entry BarriersTo China Market, 2017
Figure 48. Blood Plasma and Serum Providers High Entry BarriersTo China Market, 2017
Figure 49. Blood Plasma and Serum Providers High Entry BarriersTo China Market, 2017
Figure 50. Blood Plasma and Serum Providers High Entry BarriersTo China Market, 2017
Figure 51. Blood Plasma and Serum Providers High Entry BarriersTo China Market, 2017
Figure 52. Comparison of per capita consumptions of selected plasma products in China and the United States in 2015
Figure 53. Blood Plasma and Serum Providers Improved Fractionation Technologies for China Market, 2017
Figure 54. Blood Plasma and Serum Increasing Market Concentration Of Top Players To China Market, 2017
Figure 55. Chinese Blood Industry Vendor Competitive Strengths
Figure 56. Australia Blood Market Metrics
Figure 57. Australia Snapshot fo Blood Sector in 2018-2017
Figure 58. Thermo Fisher Scientific Revenues, United States, China, Other, Consolidated revenues
Figure 59. Plasma Components:
Figure 60. Australia Albumin
Figure 61. Indications Of Type I And Type Ii Hereditary Angioedema
Figure 62. European Centralized Authorization Procedure
Figure 63. European Community Compulsory Authorization Procedures:
Figure 64. ANZCO Foods Opportunity Created by Bovogen Biologicals Acquisition
Figure 65. ANZCO Healthcare Division Value Added By-Products Applications
Figure 66. ANZCO Foods Serum Product
Figure 67. Bovogen Biologicals Specialty Application Serum Range Features
Figure 68. Bovogen Biologicals Specialty Serums
Figure 69. Bovogen Biologicals Specialty Products
Figure 70. Bovogen Biologicals Partners
Figure 71. AusGeneX Plasma Types
Figure 72. AusGeneX Quality Serum Products Features
Figure 73. AusGeneX Bovine Serum Plasma
Figure 74. AusGeneX Purified Proteins
Figure 75. AusGeneX Products
Figure 76. VWR Product and Customer Groups 2016
Figure 77. VWR Plasma Product Portfolio in China
Figure 78. Cellsera Foetal Bovine Serum Sterile Filtered
Figure 79. Cellsera Rutherford Certificates and Accreditations
Figure 80. CellSera Products:
Figure 81. CellSera Adult Bovine Serum and Plasma
Figure 82. Cellsera State-Of-The-Art Cleanroom Laboratory
Figure 83. Cellsera Rooms Monitored By Using Real Time Fixed Particle Counters
Figure 84. Zen Bio Fetal Bovine Serum
Figure 85. Zen Bio Human Serum Item and Price
Figure 86. China Biologic Products Holdings, Regional Locations
Figure 87. China Biologic Products Holdings, Regional Locations
Figure 88. China Biologic Approved Products, Treatment/Use
Figure 89. China Biologic Products Currently in Development Treatment/Use Status of Product Development Stage*
Figure 90. China Biologic Product Holdings
Figure 91. China Biologic Fully Owned Manufacturing Facilities
Figure 92. Chinese Blood Product Industry
Figure 93. Blood Plasma and Serum Providers To China, Market Shares, Dollars, Worldwide, 2017
Figure 94. Blood Plasma and Serum Providers To China Description, 2017
Figure 95. Corning Life Sciences Revenue Structure
Figure 96. Corning Life Sciences Sera Products
Figure 97. Corning® 100 mL Human AB Serum
Figure 98. Corning Human AB Serum
Figure 99. Corning Sera in Action
Figure 100. Corning Cell Growth and Differentiation
Figure 101. Corning Cancer Research
Figure 102. Corning Cell Culture
Figure 103. Corning® Fetal Bovine Serum
Figure 104. Corning FBS Specification Customization
Figure 105. Corning FBS Serum Source
Figure 106. Corning Regional Products
Figure 107. CSL Blood Market Strategy
Figure 108. CSL Behring Sales
Figure 109. CSL Behring Regional Sales
Figure 110. ExCel Bio Fetal Bovine Serum(Standard)
Figure 111. ExCel Bio Newborn Calf Serum(Defined)
Figure 112. ExCel Bio Newborn Calf Serum(Defined)
Figure 113. GE Healthcare Calf Serum
Figure 114. GE Healthcare Calf Serum Applications
Figure 115. GE Protein Research Animal serum product sub-lots
Figure 116. Grifols SA Vertically Integrated Global Plasma Derivatives Target Markets
Figure 117. Grifols Plasma Collection
Figure 118. Grifols Product Description / Main Applications
Figure 119. Kedrion Biopharma Product Brand/Generic Name
Figure 120. Lake ImmunogenicsPlasma Antibodies
Figure 121. Lake Immunogenics Supplies Vet Schools
Figure 122. Moregate Biotech Animal Sera from Australia Or New Zealand
Figure 123. Moregate Biotech Animal Proteins Australia Or New Zealand
Figure 124. Moregate Biotech Animal Plasma Australia Or New Zealand
Figure 125. Moregate Biotech Raw Animal Material for Enzyme Extraction Australian Or New Zealand
Figure 126. Octapharma Treatment Of Patients In 113 Countries Across Three Therapeutic Areas
Figure 127. Selborne’s Manufacturing Operations General Capabilities
Figure 128. Selborne Locations
Figure 129. Selborne Facilities
Figure 130. Selborne Sourcing
Figure 131. Selborne Biological Services product range
Figure 132. Selborne Biological Services Sera
Figure 133. Selborne Biological Services Plasma
Figure 134. Selborne Microbiological Reagents
Figure 135. Selborne Sheep and Horse Microbiological Reagents
Figure 136. Rocky Mountain Biologicals Single-Source Life Science And Bioprocessing Solutions
Figure 137. Rocky Mountain Biologicals Customers
Figure 138. Shire Multi-Billion-Dollar Franchises
Figure 139. Takeda Cost Synergy Aims
Figure 140. Thermo Scientific Divisions
Figure 141. Thermo Fisher Scientific Revenues, United States, China, Other, Consolidated revenues
Figure 142. Thermo Fisher Scientific Serum and Plasma Tubes
Figure 143. Thermo Fisher Animal Serum
Figure 144. Thermo Fisher Scientific Sera Product Lines
Figure 145. Thermo Fisher Scientific Provides Customized Fetal Bovine Serum (FBS)
Figure 146. Thermo Fisher Scientific Customized Fetal Bovine Serum (FBS) Performance FBS
Figure 147. Tiantan Biological Has Five Blood Product Production Enterprises in Chengdu Rongsheng, Lanzhou Blood System, Shanghai Blood System, Wuhan Blood System and Guizhou Blood System
Figure 148. ZenBio Human Serum

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • ANZCO Foods
  • Bovogen Biologicals
  • Ausgenex Pty Ltd
  • Avantor
  • Biochrom GmbH
  • Biotest AG
  • BPL Group
  • Cellsera Rutherford
  • Changchun SRbiological
  • China Biologic Products
  • Corning Life Sciences
  • TianXinFu
  • Global Cord Blood Corp.
  • CSL
  • ExCel Bio
  • GE Healthcare Life Sciences
  • Grifols S.A. (GRFS)
  • Hualan Biological Engineering Inc.
  • Kedrion S.p.A.
  • Lake Immunogenics
  • Lanzhou Minhai
  • LFB Biotechnologies
  • Mallinckrodt
  • Merck KGaA
  • Millipore
  • Sigma-Aldrich
  • Moregate Biotech
  • Newman Biotech
  • Octopharma AG
  • Sanpower Group
  • Selborne Biological Services
  • Proliant
  • Shanghai RAAS
  • Rocky Mountain Biologicals (RMBIO)
  • Sanquin
  • Takeda
  • Shire
  • South Pacific Sera
  • Thermo Fisher Scientific
  • Beijing Tiantan Biological Products
  • Wuhan Sanli
  • Wolongsong
  • ZenBio
Note: Product cover images may vary from those shown
Adroll
adroll